The Predictive Safety Testing Consortium enables companies to share and validate safety biomarkers.

To address the issues surrounding a decade-long decrease in the number of new drug approvals, the U.S. Food and Drug Administration (FDA) in 2004 published a report titled Challenge and Opportunity on the Critical Path to New Medical Products.